Proactive Investors - Run By Investors For Investors

Amryt Pharma making strong progress with momentum continuing to build

The company is a rarity among the junior drug companies because it has a successful and revenue generating product out on the market and a promising drug in the final stages of clinical development
researcher filling a vial at microscope
It expects to deliver an interim read-out from its phase III study in the fourth quarter

Amryt Pharma PLC (LON:AMYT) said strong progress had been made commercially and in the clinic in the first-half of 2018.

The company, which develops and sells drugs for rare and orphan diseases, posted revenues of €7mln, up 14% on the year earlier. Based on the current run rate, the year-end result will be in line with forecasts.

Amryt derives its sales from Lojuxta a drug that treats a rare condition called Homozygous Familial Hypercholesterolaemia (HoFH), which results in aggressive and premature heart disease.

The group has developed a network of distributors for the product, while in the UK it made a significant breakthrough by being reimbursed by NHS England for Lojuxta.

CEO pleased 

Chief executive Joe Wiley said he was “pleased by the progress” made in the first-half.

“Our focus on adoption of and access to Lojuxta in new and existing territories is already delivering significant returns and we are confident that this positive momentum will continue in 2018 and beyond,” he added.

Amryt also has a phase III drug, AP101 for epidermolysis bullosa (EB), a rare genetic skin disorder.

Update expected in Q4

It said its EASE clinical study was “progressing well” with an interim efficacy analysis expected in the final quarter of the year.

The company has also licenced into the portfolio an early-stage EB treatment, a non-viral gene therapy platform with preliminary data. Results from pre-clinical work are expected towards the end of the year.

It told investors it was “actively seeking to acquire new commercial stage assets that can further leverage its established commercial, medical and regulatory infrastructure”.

Financially, Amryt is well placed with €12.2mln in the bank at the end of June.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use